Novartis, of Swiss pharmaceuticals, reported more than expected first-quarter sales on Tuesday and improved full-year guidance.

Net sales rose 15% on a constant currency basis to $13.2 billion, while analysts estimated $13.12 billion in the LSEG poll.

Corresponding quarterly operating income rose 27% to $5.58 billion, compared with an expected $5.07 billion.

Novartis also proposed a full-year guide for 2025, predicting net sales will increase through high digital and core operating income to increase double digits. The company had previously forecasted net sales growth to medium-rise figures and core operating income growth from high-unit to low binary figures.

Sales continue to be driven primarily by the company's large heart failure drug and arthritis drug Cosentyx. However, CEO VAS Narasimhan highlighted the growing demand for its Kisqali breast cancer treatment, Kesimpta multiplexed viral drugs and LEQVIO cholesterol drugs.

"Our priority brands, including Kisqali, Kesimpta and Leqvio, continue to show strong momentum, which we expect will drive our growth to 2030 and beyond," Narasimhan said in a statement.

The CEO also pointed to a new approval for a range of other drugs, including its Pluvicto Prostate cancer treatment.

"We remain focused on advancing our leading pipeline and are confident in achieving our growth prospects," Narasimhan added.

The global pharmaceutical industry waited for anticipated tariffs in respiratory periods after the global pharmaceutical industry surveyed the industry earlier this month.

So far, drugs have exempted huge import tariffs, but Trump warned in March that targeted drug taxes will be "in the near future."

European pharmaceutical companies are trying to retain lucrative markets and simplify domestic production opportunities, and European pharmaceutical companies' investments have boosted investment in the United States.

Novartis announced earlier this month that it would invest $23 billion to build and expand 10 facilities in the U.S. over the next five years, and said it would ensure that all major Novartis drugs for U.S. patients will be manufactured domestically.

Narasimhan, who has long been bullish on his company's growth in the U.S. market, said the tariffs were taken into account the company's decision, but not the driver.

In Tuesday's results, the company focused on "priority geography" in the United States, China, Germany and Japan.

Swiss pharmaceutical company Roche followed up last week, which guaranteed $50 billion in the U.S. investment over the next five years and created more than 12,000 jobs.

Meanwhile, American companies Johnson and Johnson and Yililai A large number of new investments in the United States have also been announced recently